Jing Zhao

Jing Zhao

Auto-generated profile, based on publicly available information

Jing Zhao

The Affiliated Hospital of Qingdao University

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Pathology - Research and Practice
Verified
Journal Article
Closed access
JZJing Zhao
Jing Zhao
UKUma Krishnamurti
Uma Krishnamurti
CZChao Zhang
Chao Zhang
JMJane Meisel
Jane Meisel
ZWZhimin Wei
Zhimin Wei
XLXiaoxian Li
Xiaoxian Li

1 January 2016 in Cancer Biology & Medicine
Verified
Journal Article
Open access
PDF file
HNHai-Fei Niu
Hai-Fei Niu
LWLi-Juan Wei
Li-Juan Wei
YJYU Jinpu
YU Jinpu
ZLZhen Lian
Zhen Lian
JZJing Zhao
Jing Zhao
JLJuntian Liu
Juntian Liu
Objective: Survival and treatment of patients with microinvasive breast cancer (MIBC) remain controversial. In this paper, weevaluated whether adjuvant chemotherapy is necessary for patients with MIBC to identify risk factors influencing its prognosis anddecide the indication for adjuvant chemotherapy. Methods: In this retrospective study, 108 patients with MIBC were recruited according to seventh edition of the staging manual ofthe American Joint Committee on Cancer (AJCC). The subjects were divided into chemotherapy and non-chemotherapy groups.We compared the 5-year disease-free survival (DFS) and overall survival (OS) rates between groups. Furthermore, we analyzed thefactors related to prognosis for patients with MIBC using univariate and multivariate analyses. We also evaluated the impact ofadjuvant chemotherapy on the prognostic factors by subgroup analysis after median follow-up time of 33 months (13-104months). Results: The 5-year DFS and OS rates for the chemotherapy group were 93.7% and 97.5%, whereas those for the nonchemotherapygroup were 89.7% and 100%. Results indicate that 5-year DFS was superior, but OS was inferior, in the formergroup compared with the latter group. However, no statistical significance was observed in the 5-year DFS (P=0.223) or OS(P=0.530) rate of the two groups. Most relevant poor-prognostic factors were Ki-67 overexpression and negative hormonalreceptors. Cumulative survival was 98.2% vs. 86.5% between low Ki-67 (≤20%) and high Ki-67 (>20%). The hazard ratio ofpatients with high Ki-67 was 16.585 [95% confidence interval (CI), 1.969-139.724; P=0.010]. Meanwhile, ER(-)/PR(-) patientswith MIBC had cumulative survival of 79.3% compared with 97.5% for ER(+) or PR(+) patients with MIBC. The hazard ratio forER(-)/PR(-) patients with MIBC was 19.149 (95% CI, 3.702-99.057; P<0.001). Subgroup analysis showed that chemotherapy couldimprove the outcomes of ER(-)/PR(-) patients (P=0.014), but not those who overexpress Ki-67 (P=0.105). Conclusions: Patients with MIBC who overexpress Ki-67 and with negative hormonal receptors have relatively substantial risk ofrelapse within the first five years after surgery. However, adjuvant chemotherapy can only improve the outcomes of ER(-)/PR(-)patients, but not those who overexpress Ki-67. Further studies with prolonged follow-up of large cohorts are recommended toassess the prognostic significance and treatment of this lesion.

27 April 2026 in Cell Cycle
Verified
Journal Article
Closed access
JZJing Zhao
Jing Zhao
WZWei Zhao
Wei Zhao
ZWZhimin Wei
Zhimin Wei
FHFeng Hou
Feng Hou
LSLingling Sun
Lingling Sun
XDXianning Dong
Xianning Dong
Breast cancer (BC) exhibits significant heterogeneity and complexity and is leading causes of mortality in women globally. Paclitaxel (PTX) is commonly utilized as the primary medication for BC. However, the resistance of BC to PTX poses a significant challenge in clinical treatment. This study aimed at to explore whether carboxy-terminal domain small phosphatase like 2 (CTDSPL2) affected PTX resistance in BC cells. PTX resistant BC cell lines, including MCF-7/PTX and MDA-MB-231/PTX, were developed by continuously increasing PTX concentration, and we found that CTDSPL2 was upregulated in BC cells with PTX resistance. Loss-of-function studies showed that CTDSPL2 knockdown caused a decrease in cytotoxicity and proliferative ability in PTX-resistant BC cells, as well as enhanced cell apoptotic rate and DNA damage. The results from nanoparticle tracking analysis (NTA) indicated that CTDSPL2 knockdown also suppressed the secretion of extracellular vesicles. In vivo tumorigenesis assays showed that CTDSPL2 downregulation inhibited tumorigenicity of nude mice injecting with PTX-resistant BC cells. Co-immunoprecipitation (Co-IP) assay demonstrated the binding between CTDSPL2 and SCY1-like pseudokinase 1 (SCYL1). The increased level of SCYL1 phosphorylation evoked by CTDSPL2 knockdown in PTX-resistant cancer cells was blocked after mutating the serine 754 site of SCYL1 to alanine. In conclusion, the present study identifies CTDSPL2 as a new factor in BC that plays an essential role in PTX-resistant BC cells through the regulation of SCYL1 phosphorylation.